RondinX’s New Microbiome Platform a Potential Tool for IBD Drug Discovery

RondinX’s New Microbiome Platform a Potential Tool for IBD Drug Discovery
RondinX has developed a breakthrough platform that profiles and predicts gut microbial growth dynamics by using genetic material of human gut samples. The technology may be key to understanding the interaction between changes in the gut microbiome and health, specifically the development of conditions like inflammatory bowel disease (IBD). The novel approach, established at the Weizmann Institute of Science and licensed to RondinX from its commercial arm YEDA Research and Development Company, adds a new dimension to the microbiome drug development process, and has important implications for IBD, a group of diseases associated with changes in bacterial growth rates. The company is currently working with Professors Eran Segal and Eran Elinav at Weizmann, both leading experts in the microbiome field. “RondinX’s approach takes into account that the microbiome represents a highly dynamic ecosystem and can differ greatly from one day to the next, from individual to individual and even in patients suffering from the same disease," Guy Harmelin, co-founder and CEO of RondinX, said in a press release. "By analyzing the patient’s microbiome of tomorrow, today, we are taking the next steps in transforming microbiome knowledge to cures.” "We believe that the unique insight into the microbiome dynamics provided by our platform will give RondinX and our future partners a leading edge in microbiome drug discovery and development," he added. A person's microbiota consists of the 10 trillion to 100 trillion microbial cells,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *